Okay, I will analyze the VBL.NS stock report to identify a potential trade setup with a 5%-15% upside over the next 1-4 months.

**Step 1: Audit the Data**

*   **Data Present:** Daily price chart, fundamental analysis (both short-term and long-term), relative strength analysis, EMA crossover summary, Bollinger Bands summary, Supertrend analysis, MACD summary, Volatility Squeeze analysis, RSI-Volume analysis.
*   **Data Missing:** Weekly price chart, deeper fundamental analysis (balance sheet, cash flow statements), broader sector analysis.
*   **Confidence Level:** **Medium**. The report provides a reasonable overview of the stock's technical and fundamental situation, but the lack of weekly charts and more granular fundamental data (like balance sheet data) limits the confidence level.

**Step 2: Analyze the Setup**

*   **Price Structure:** The 3-year daily chart shows a significant uptrend peaking in late 2024/early 2025. The price has since corrected and appears to be in a consolidation phase, finding support around INR 450.

*   **Trend Direction:**
    *   **Long-term:** The fundamentals suggest growth over the past 4 years.
    *   **Intermediate-term:** The EMA crossover summary indicates a short-term uptrend as the 20-day EMA is above the 50-day EMA. The Supertrend indicator confirms an uptrend signal from late November 2025.
    *   **Short-term:** The MACD is bearish and the RSI is around 48, indicating neutral momentum.

*   **Momentum:** The RSI isn't showing oversold conditions, suggesting there might be room for further downside or consolidation before an upward move. Volatility is currently low (Volatility Squeeze Summary).

*   **Confluence:** There is some positive confluence:
    *   Short-term uptrend (EMA and Supertrend).
    *   Long-term positive growth (Fundamentals).
    *   Relative Strength is outperforming the benchmark index (but medium-term relative strength is lagging).

**Step 3: Formulate the Recommendation**

Given the current situation, a "no entry" recommendation is appropriate, as I lack the appropriate conviction. Although there are some positive signs, the current consolidation phase and bearish MACD signal suggest caution.

**Conditional Plan:**

A potential buy setup could arise if the following conditions are met:

*   **Condition to Buy:** A decisive break above the 50-day EMA (INR 469.33) with confirmed by a bullish MACD crossover. Wait for the close above 475.
*   **Entry Price:** INR 475 (after the confirmation)
*   **<b><font color='#c0392b'>Stop Loss</font></b>:** INR 450 (just below the recent support level)
*   **<b><font color='#27ae60'>Take Profit</font></b>:** INR 520 (approximately 10% above entry and aligns with previous resistance)

I will reassess once all the conditions are met.


# News & Analyst Targets
Okay, I will act as a stock research analyst and gather the latest information on VBL (presumably VolitionRx Limited) for you. Here's what I've found this week, presented as you requested:

Here's a summary of the news and analysis on VolitionRx Limited (VBL/VNRX):

### 1. Latest News for VBL This Week (December 16-20, 2025):

*   **Business Review 2025:** On December 17, 2025, Volition issued its Business Review 2025, highlighting commercial, clinical, and IP milestones related to the commercialization of its Nu.Q platform. Key achievements included:
    *   The first clinical order for Nu.Q Cancer assays for lung cancer.
    *   Inclusion of the Nu.Q NETs assay in a government-backed French sepsis evaluation (worth approximately $7.3 million).
    *   First revenue from the CE-Marked Nu.Q NETs automated assay.
    *   Signing human-licensing agreements with Werfen and Hologic.
    *   A payable $5 million contractual milestone tied to feline lymphoma results.
*   **Capture-Seq™ Advancement:** On December 11, 2025, Volition announced a preprint describing Capture-Seq™, a method that enriches ultrashort transcription factor-bound cfDNA for liquid biopsy, achieving 180-fold (18,000%) enrichment. In a small training cohort, analysis reportedly achieved 100% sensitivity and 100% specificity.
*   **Lung Cancer Abstracts:** On December 8, 2025, Volition announced that two abstracts were presented at the North America Conference on Lung Cancer.
*   **Nu.Q® NETs Assay in France's Sepsis Evaluation:** On December 4, 2025, VolitionRx Limited announced the inclusion of its Nu.Q® NETs Assay as an innovative biomarker in France's real-world evaluation of early detection of sepsis.

### 2. Brokerage Upgrades/Downgrades for VBL:

*   On November 18, 2025, Investing.com reported that H.C. Wainwright lowered its price target on VolitionRX (NYSE:VNRX) to $1.50 from $2.50, while maintaining a Buy rating.
*   On November 17, 2025, Investing.com reported that Freedom Capital Markets reduced its price target on VolitionRX (NYSE:VNRX) to $1.00 from $2.00.

### 3. Other News Impacting VBL:

*   **Public Offering:** In October 2025, VolitionRx Limited announced the pricing of a $6.0 million underwritten public offering of common stock and common stock warrants.

### 4. Analyst Targets for VBL:

It appears there is conflicting information. Here's a summary of price targets from several sources:

| Source                                 | Average Price Target (INR) | High Price Target (INR) | Low Price Target (INR) |
| :------------------------------------- | :------------------------- | :------------------------ | :----------------------- |
| TipRanks                                | 560.00                     | 570.00                    | 550.00                   |
| Alpha Spread                             | 609.82                     | 781.2                     | 505                       |
| MarketScreener                           | 597.52                     | 744.00                    | 500.00                   |

**Please Note:**

*   Some sources list price targets in INR (Indian Rupees), while others may be in USD (United States Dollar). Please clarify the currency if needed.
*   Analyst ratings and price targets can vary significantly and should not be the sole basis for investment decisions.

**Disclaimer:** I am an AI chatbot and cannot provide financial advice. This information is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.
